Year: 2023

Expands Reach Beyond Current Partnerships and Integration Agreements OCOEE, FL, Nov. 07, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – iCoreConnect, Inc. (NASDAQ: ICCT)(“iCore” or the “Company”) a cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise and healthcare workflow platform, today announced the release of a new patient import tool for iCoreVerify, the Company’s automated insurance verification software solution. The new module expands the connectivity and integration capabilities beyond the current Practice Management Systems and enables compatibility with all systems. This additional compatibility broadens the potential customer base and increases the addressable market for the Company’s fast-growing iCoreVerify software. Among the module’s...

LAS VEGAS, Nov. 07, 2023 (GLOBE NEWSWIRE) — via IBN / GEMXX Corporation (OTC: GEMZ) (“GEMXX” or the “Company”), a leader in the ammolite gemstone mine-to-market segment and a partner in Canadian gold exploration company Crazy Horse Mining, Inc. (“CHMI” or “Crazy Horse”), is pleased to provide investors with an update on its current and future plans. The Company is highlighting the 2023 mining season. GEMXX has achieved significant milestones recently and it’s worth noting that the Company continues to control each stage of its production including gold mining, gemstone production, jewelry manufacturing and global distribution. Further, the Company continues to expand while avoiding long-term debt. GEMXX has set aggressive but achievable goals for its mining division. During 2023 the Company intended...

NEW YORK, NY, Nov. 07, 2023 (GLOBE NEWSWIRE) — Elys Game Technology, Corp. (“Elys” or the “Company”) (OTC:ELYS) (BER:3UW), an interactive gaming and sports betting technology company, today announced a market access agreement with Caesars Entertainment that unlocks immediate access to the lucrative Colorado sports betting market. This strategic agreement signals Elys’ first entry into the North American mobile sports betting landscape. With the introduction of the Company’s “5D by Elys” mobile app under the recently unveiled SportBet.com brand, the Company presents a comprehensive sports betting platform enriched with advanced features and seamless cross-platform compatibility. This agreement potentially positions Elys for a strategic launch of its North American online sports betting aspirations. “We are focused on converting...

CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors. The first clinical site is located at START Midwest in Grand Rapids, Michigan. QN-302 works by selectively stabilizing G4 complexes prevalent in the promoter region of oncogenes in many tumor types, impeding transcription of G4-containing cancer genes, and may potentially offer a tumor-agnostic clinical approach to treatment. It was discovered...

FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months Future development activities were identified; Salarius intends to submit an amended Ewing sarcoma clinical trial protocol HOUSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that it participated in a Type B End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to receive guidance regarding the development program for seclidemstat to treat Ewing sarcoma. The Company has received the final meeting minutes and is amending the current clinical trial protocol to reflect guidance agreed to with FDA during the EOP2 meeting. As previously reported on August 8,...